WO2011057108A1 - Ophthalmic formulations containing substituted gamma lactams and methods for use thereof - Google Patents
Ophthalmic formulations containing substituted gamma lactams and methods for use thereof Download PDFInfo
- Publication number
- WO2011057108A1 WO2011057108A1 PCT/US2010/055685 US2010055685W WO2011057108A1 WO 2011057108 A1 WO2011057108 A1 WO 2011057108A1 US 2010055685 W US2010055685 W US 2010055685W WO 2011057108 A1 WO2011057108 A1 WO 2011057108A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- active agent
- therapeutically active
- concentration
- benzalkonium chloride
- Prior art date
Links
- 0 BN(C(*C(O*)=O)CC1)C1=O Chemical compound BN(C(*C(O*)=O)CC1)C1=O 0.000 description 1
- GKRBCKDGBDUAIQ-URXFXBBRSA-N CCCCC[C@@H](c(cc1)ccc1N([C@@H](CCCc1ccc(C(OC(C)C)=O)[s]1)CC1)C1=O)O Chemical compound CCCCC[C@@H](c(cc1)ccc1N([C@@H](CCCc1ccc(C(OC(C)C)=O)[s]1)CC1)C1=O)O GKRBCKDGBDUAIQ-URXFXBBRSA-N 0.000 description 1
- GKRBCKDGBDUAIQ-XUZZJYLKSA-N CCCCC[C@H](c(cc1)ccc1N([C@@H](CCCc1ccc(C(OC(C)C)=O)[s]1)CC1)C1=O)O Chemical compound CCCCC[C@H](c(cc1)ccc1N([C@@H](CCCc1ccc(C(OC(C)C)=O)[s]1)CC1)C1=O)O GKRBCKDGBDUAIQ-XUZZJYLKSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112012010795A BR112012010795A2 (en) | 2009-11-05 | 2010-11-05 | OPHTHALMIC FORMULATIONS CONTAINING SUBSTITUTED RANGE LACTAMS AND METHODS FOR THEIR USE |
JP2012538041A JP2013510172A (en) | 2009-11-05 | 2010-11-05 | Ophthalmic preparations containing substituted gamma lactams and methods of use thereof |
CA2780268A CA2780268C (en) | 2009-11-05 | 2010-11-05 | Ophthalmic formulations containing substituted gamma lactams and methods for use thereof |
AU2010315051A AU2010315051B2 (en) | 2009-11-05 | 2010-11-05 | Ophthalmic formulations containing substituted gamma lactams and methods for use thereof |
RU2012122614A RU2630594C2 (en) | 2009-11-05 | 2010-11-05 | Ophthalmatic compositions containing substituted gamma-lactames and methods of their application |
EP10779166.7A EP2496214B1 (en) | 2009-11-05 | 2010-11-05 | Ophthalmic formulations containing substituted gamma lactams and methods for use thereof |
CN2010800551803A CN102655854A (en) | 2009-11-05 | 2010-11-05 | Ophthalmic formulations containing substituted gamma lactams and methods for use thereof |
KR1020127014537A KR101805939B1 (en) | 2009-11-05 | 2010-11-05 | Ophthalmic formulations containing substituted gamma lactams and methods for use thereof |
ES10779166T ES2864735T3 (en) | 2009-11-05 | 2010-11-05 | Ophthalmic formulations containing substituted gamma-lactams and methods for the use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25830809P | 2009-11-05 | 2009-11-05 | |
US61/258,308 | 2009-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011057108A1 true WO2011057108A1 (en) | 2011-05-12 |
Family
ID=43416423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/055685 WO2011057108A1 (en) | 2009-11-05 | 2010-11-05 | Ophthalmic formulations containing substituted gamma lactams and methods for use thereof |
Country Status (13)
Country | Link |
---|---|
US (1) | US8952051B2 (en) |
EP (1) | EP2496214B1 (en) |
JP (2) | JP2013510172A (en) |
KR (1) | KR101805939B1 (en) |
CN (2) | CN106176574A (en) |
AR (1) | AR078928A1 (en) |
AU (1) | AU2010315051B2 (en) |
BR (1) | BR112012010795A2 (en) |
CA (1) | CA2780268C (en) |
ES (1) | ES2864735T3 (en) |
RU (1) | RU2630594C2 (en) |
TW (1) | TWI586665B (en) |
WO (1) | WO2011057108A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014531401A (en) * | 2011-07-26 | 2014-11-27 | アラーガン インコーポレイテッドAllergan,Incorporated | Two-part formulation for ocular delivery |
JP2015500347A (en) * | 2011-12-16 | 2015-01-05 | アラーガン インコーポレイテッドAllergan,Incorporated | Ophthalmic composition comprising polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201733577A (en) * | 2016-03-14 | 2017-10-01 | Santen Pharmaceutical Co Ltd | Pharmaceutical composition containing dorzolamide, timolol, and surfactant |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998041208A1 (en) * | 1997-03-17 | 1998-09-24 | Novartis Ag | Compositions and methods for reducing ocular hypertension |
US20020002185A1 (en) * | 1997-03-17 | 2002-01-03 | Reed Kenneth Warren | Compositions and methods for reducing ocular hypertension |
US7476747B2 (en) | 2005-03-10 | 2009-01-13 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
WO2010041722A2 (en) * | 2008-10-07 | 2010-04-15 | R-Tech Ueno, Ltd. | Pharmaceutical composition |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6124344A (en) * | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
SI1759702T1 (en) * | 2004-05-26 | 2009-06-30 | Bayardo Arturo Jimenez | Method of preparing a latanoprost ophthalmic solution and solution thus produced |
US7091231B2 (en) * | 2004-12-10 | 2006-08-15 | Allergan, Inc. | 12-Aryl prostaglandin analogs |
US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
AU2007226957B2 (en) * | 2006-03-20 | 2013-08-15 | Allergan, Inc. | Substituted gamma lactams as prostaglandin EP2 agonists |
-
2010
- 2010-11-04 US US12/939,846 patent/US8952051B2/en active Active
- 2010-11-05 EP EP10779166.7A patent/EP2496214B1/en active Active
- 2010-11-05 CA CA2780268A patent/CA2780268C/en active Active
- 2010-11-05 RU RU2012122614A patent/RU2630594C2/en active
- 2010-11-05 AU AU2010315051A patent/AU2010315051B2/en active Active
- 2010-11-05 JP JP2012538041A patent/JP2013510172A/en not_active Withdrawn
- 2010-11-05 CN CN201610726830.1A patent/CN106176574A/en active Pending
- 2010-11-05 ES ES10779166T patent/ES2864735T3/en active Active
- 2010-11-05 TW TW099138230A patent/TWI586665B/en active
- 2010-11-05 CN CN2010800551803A patent/CN102655854A/en active Pending
- 2010-11-05 KR KR1020127014537A patent/KR101805939B1/en active IP Right Grant
- 2010-11-05 BR BR112012010795A patent/BR112012010795A2/en not_active IP Right Cessation
- 2010-11-05 WO PCT/US2010/055685 patent/WO2011057108A1/en active Application Filing
- 2010-11-05 AR ARP100104121A patent/AR078928A1/en not_active Application Discontinuation
-
2016
- 2016-07-15 JP JP2016140448A patent/JP6026699B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998041208A1 (en) * | 1997-03-17 | 1998-09-24 | Novartis Ag | Compositions and methods for reducing ocular hypertension |
US20020002185A1 (en) * | 1997-03-17 | 2002-01-03 | Reed Kenneth Warren | Compositions and methods for reducing ocular hypertension |
US7476747B2 (en) | 2005-03-10 | 2009-01-13 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
WO2010041722A2 (en) * | 2008-10-07 | 2010-04-15 | R-Tech Ueno, Ltd. | Pharmaceutical composition |
Non-Patent Citations (1)
Title |
---|
JIAO ET AL: "Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 60, no. 15, 14 December 2008 (2008-12-14), pages 1663 - 1673, XP025656960, ISSN: 0169-409X, [retrieved on 20080920], DOI: 10.1016/J.ADDR.2008.09.002 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014531401A (en) * | 2011-07-26 | 2014-11-27 | アラーガン インコーポレイテッドAllergan,Incorporated | Two-part formulation for ocular delivery |
JP2018062521A (en) * | 2011-07-26 | 2018-04-19 | アラーガン、インコーポレイテッドAllergan,Incorporated | Two part formulation for ophthalmic delivery |
US10314887B2 (en) | 2011-07-26 | 2019-06-11 | Allergan, Inc. | Two part formulation system for ophthalmic delivery |
JP2015500347A (en) * | 2011-12-16 | 2015-01-05 | アラーガン インコーポレイテッドAllergan,Incorporated | Ophthalmic composition comprising polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer |
Also Published As
Publication number | Publication date |
---|---|
TW201130826A (en) | 2011-09-16 |
AU2010315051B2 (en) | 2016-06-02 |
JP2013510172A (en) | 2013-03-21 |
EP2496214B1 (en) | 2021-01-06 |
ES2864735T3 (en) | 2021-10-14 |
BR112012010795A2 (en) | 2017-08-15 |
US20110105581A1 (en) | 2011-05-05 |
RU2630594C2 (en) | 2017-09-11 |
CA2780268A1 (en) | 2011-05-12 |
KR101805939B1 (en) | 2017-12-06 |
CN106176574A (en) | 2016-12-07 |
CA2780268C (en) | 2018-05-15 |
RU2012122614A (en) | 2013-12-10 |
TWI586665B (en) | 2017-06-11 |
EP2496214A1 (en) | 2012-09-12 |
AU2010315051A1 (en) | 2012-05-31 |
KR20120124059A (en) | 2012-11-12 |
US8952051B2 (en) | 2015-02-10 |
AR078928A1 (en) | 2011-12-14 |
CN102655854A (en) | 2012-09-05 |
JP6026699B1 (en) | 2016-11-16 |
JP2017014222A (en) | 2017-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2763654B1 (en) | Ophthtalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid | |
AU2005320085B2 (en) | Preventive or therapeutic agent for glaucoma | |
EP1808170B1 (en) | Aqueous eye drops with accelerated intraocular migration | |
US11389441B2 (en) | Ophthalmic compositions | |
CN105012964A (en) | Pharmaceutical compositions having desirable bioavailability | |
WO1993024121A1 (en) | Remedy for glaucoma | |
JP6026699B1 (en) | Ophthalmic preparations containing substituted gamma lactams and methods of use thereof | |
JP2022116147A (en) | Ophthalmic compositions containing nitric oxide releasing prostamide | |
WO2016171152A1 (en) | Therapeutic agent, improving agent, and preventative agent for corneal disorders | |
CN102695498A (en) | Compositions & methods for lowering intraocular pressure | |
CN102762195A (en) | Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof | |
US20080051406A1 (en) | Brimonidine and timolol compositions | |
EP3730137B1 (en) | Therapeutic agent for glaucoma comprising an fp agonist and timolol | |
US20210299121A1 (en) | Cetirizine ophthalmic compositions | |
WO2008024846A2 (en) | Brimonidine and timolol compositions | |
WO2024034592A1 (en) | Aqueous pharmaceutical composition containing udca or salt thereof | |
JP2009528390A (en) | Medicinal latrunculin preparation | |
CA3138510A1 (en) | Pharmaceutical compositions for treating presbyopia and methods for fabricating thereof | |
KR20140050080A (en) | N,n-dialkylalkylenyl esters, compositions thereof, and methods for use thereof | |
JP2001089366A (en) | Cornea turbidity inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080055180.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10779166 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2780268 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010315051 Country of ref document: AU Ref document number: 2012538041 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4705/DELNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2010315051 Country of ref document: AU Date of ref document: 20101105 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010779166 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20127014537 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012122614 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012010795 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012010795 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120507 |